Allegations of Research Misconduct

Pharmatera Journal is committed to maintaining the highest standards of research integrity, transparency, and ethical scholarly publishing. The journal takes all allegations of research misconduct seriously and handles them fairly, objectively, and confidentially in accordance with the principles and guidelines established by the Committee on Publication Ethics (COPE).

Research misconduct includes fabrication, falsification, plagiarism, citation manipulation, unethical research practices, and other serious violations that compromise the integrity and reliability of scientific research.

1. Definition of Research Misconduct

Research misconduct refers to unethical practices occurring during the design, conduct, analysis, review, reporting, or publication of scientific research.

Such misconduct may include:

  1. Fabrication: Making up research data, findings, or results and presenting them as genuine.

  2. Falsification: Manipulating research materials, equipment, procedures, data, or results in ways that misrepresent the research findings.

  3. Plagiarism: Using another person's ideas, words, data, or research findings without appropriate acknowledgment.

  4. Citation Manipulation: Inappropriately adding, excluding, or manipulating references to increase citation counts or influence scientific impact.

  5. Duplicate or Redundant Publication: Publishing substantially similar research findings in multiple publications without appropriate disclosure.

  6. Authorship Misconduct: Inappropriately assigning, excluding, or modifying authorship without legitimate intellectual contributions or consent.

  7. Ethical Violations: Conducting research involving human participants or animals without required ethical approval or failing to comply with applicable ethical standards.

  8. Peer-Review Manipulation: Attempting to influence, falsify, or compromise the integrity of the peer-review process.

2. Reporting Allegations of Research Misconduct

Pharmatera Journal encourages authors, reviewers, editors, readers, and other concerned parties to report suspected research misconduct.

Allegations should be submitted to the Editorial Office of Pharmatera Journal and should include sufficient supporting information, such as manuscript details, relevant evidence, and a clear description of the suspected violation.

The journal will assess allegations based on the available evidence, regardless of whether the concerns arise before or after publication.

The identity of individuals reporting suspected misconduct will be treated confidentially to the extent reasonably possible and permitted by applicable procedures.

3. Initial Assessment of Allegations

Upon receiving an allegation of research misconduct, the Editor-in-Chief or a designated editor will conduct an initial assessment to determine whether the concern is credible and falls within the scope of research or publication misconduct.

The initial assessment may include:

  1. Reviewing the submitted allegations and supporting evidence.

  2. Examining relevant manuscripts, published articles, research data, and editorial records.

  3. Identifying potential conflicts of interest among the parties involved.

  4. Determining whether further investigation or clarification is necessary.

Allegations without sufficient evidence may be closed following an appropriate assessment. However, credible concerns will be examined further.

4. Investigation Procedures

When there is reasonable evidence of potential research misconduct, Pharmatera Journal will initiate an appropriate investigation in accordance with COPE recommendations.

The investigation process may involve:

  1. Notification to Authors: The corresponding author will be informed of the allegations and invited to provide a detailed explanation on behalf of the authors, where appropriate.

  2. Evaluation of Responses: The Editorial Board will assess the authors' explanations and supporting documentation.

  3. Independent Expert Review: Independent reviewers or subject-matter experts may be consulted when specialized scientific or methodological evaluation is required.

  4. Institutional Involvement: If necessary, the journal may refer the matter to the authors' affiliated institutions or relevant research integrity authorities for further investigation.

  5. Editorial Decision: The Editor-in-Chief will determine appropriate editorial action based on the available evidence and any relevant institutional findings.

All parties involved will be treated fairly and given an appropriate opportunity to respond to concerns affecting them.

5. Editorial Actions and Sanctions

Depending on the nature and severity of the confirmed misconduct, Pharmatera Journal may take one or more of the following actions:

a. Manuscript Revision or Clarification

For minor errors or concerns that do not constitute serious misconduct, authors may be requested to provide clarification, additional analysis, corrected information, or manuscript revisions.

b. Manuscript Rejection

Manuscripts containing confirmed serious misconduct may be rejected at any stage of the editorial or peer-review process.

c. Publication of a Correction

If errors are identified in a published article but the overall scientific findings remain reliable, the journal may issue a correction to maintain the accuracy of the scientific record.

d. Expression of Concern

An expression of concern may be published when credible allegations raise serious questions about a published article but the investigation remains inconclusive or unresolved.

e. Article Retraction

A published article may be retracted when serious misconduct or other fundamental problems render its findings unreliable or its publication unethical.

f. Institutional Notification

The journal may notify relevant academic institutions, research organizations, or appropriate authorities when serious misconduct requires further investigation or institutional action.

6. Handling Misconduct Before Publication

When suspected research misconduct is identified during manuscript submission, editorial screening, or peer review, the Editorial Board will assess the concern before making a final publication decision.

The manuscript may be placed on hold while the allegations are examined. Authors may be requested to provide supporting documents, original research data, ethical approval records, or additional explanations.

If serious misconduct is confirmed, the manuscript will be rejected in accordance with the journal's editorial policies.

7. Handling Misconduct After Publication

When allegations arise after an article has been published, Pharmatera Journal will conduct an appropriate assessment to determine whether the integrity of the published scientific record has been compromised.

If misconduct or significant errors are established, the journal may issue a correction, expression of concern, or retraction, depending on the circumstances.

Retraction notices and other post-publication editorial statements will be clearly identified and linked to the original article whenever applicable.

8. Confidentiality and Fairness

Pharmatera Journal is committed to handling all allegations of research misconduct with confidentiality, impartiality, and procedural fairness.

Information related to allegations and investigations will only be disclosed to individuals or institutions with legitimate responsibilities in resolving the matter.

Editors and reviewers involved in investigations must disclose potential conflicts of interest and withdraw from the process when their impartiality may be compromised.

The journal does not tolerate knowingly false or malicious allegations intended to damage the reputation of researchers or institutions.

9. Responsibilities of Authors

Authors are responsible for ensuring that their research complies with ethical standards and that all submitted data, findings, and statements are accurate and verifiable.

When concerns regarding research integrity arise, authors are expected to cooperate with the Editorial Board by providing relevant documentation, explanations, or original research data when reasonably requested and permitted by applicable ethical and legal requirements.

Failure to cooperate may be considered during editorial assessment but does not, by itself, establish research misconduct.

10. Commitment to Research Integrity

Pharmatera Journal is dedicated to protecting the integrity of the scientific literature and promoting responsible research and publication practices.

All allegations of research misconduct will be evaluated carefully, and editorial decisions will be based on available evidence, established ethical standards, and applicable COPE guidance.

The journal recognizes that determining research misconduct may require investigation by the relevant institution or research authority. Pharmatera Journal will cooperate with such investigations while independently fulfilling its responsibility to maintain the accuracy and integrity of the published scholarly record.

Reference:

Committee on Publication Ethics (COPE). Guidelines and resources on research integrity and publication misconduct.

https://publicationethics.org/